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PURPOSE: Sentinel lymph node biopsy (SLNB) has been rapidly adopted by surgical oncologists in the
management of invasive breast cancer. This study reviews the Royal Australasian College of Surgeons (RACS)
Sentinel Node versus Axillary Clearance (SNAC) trial and reports an interim analysis of the first 150 subjects.
Other currently open multi-institutional randomized trials in SLNB are reviewed.
METHODS: The SNAC trial is a multicentre, centrally randomized, phase III clinical trial. Subjects are ran-
domized to SLNB alone (with completion axillary clearance, AC, for sentinel node-positive patients) or AC plus
SLNB, with stratification according to age (< 50 years, * 50 years), primary tumour palpability (palpable vs
impalpable), lymphatic mapping technique (blue dye plus scintigraphy vs blue dye alone) and centre.
RESULTS: The trial was launched in May 2001 in two centres. Randomization continues currently at the rate of
approximately 30 subjects per month (total, 1,012 at the time of writing) from 32 participating centres in Australia
and New Zealand. Data from the first 150 subjects have been analysed to assess: compliance with randomized
treatment allocation; measures of test performance for SLNB (detection, removal, sensitivity, specificity and false-
negative rates); measures of arm volume, function, symptoms and quality of life; and sample size estimates.
CONCLUSIONS: The SNAC trial is one of the fastest accruing clinical trials in Australasia. It is on track to
determine whether differences in morbidity, with equivalent cancer-related outcomes, exist between SLNB and
AC for women with early breast cancer. [Asian J Surg 2004;27(4):284–90]
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Introduction
Axillary clearance (AC) is the standard of care in Australia for
the management of the axilla in invasive breast cancer. The
benefits of AC in terms of staging disease and locoregional
control are well documented, but there is associated morbid-
ity.1–3 A proven method of providing accurate prediction of
axillary lymph node status that reduces the risk of lymph-
© 2004 Elsevier. All rights reserved.
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oedema and other complications of AC would be a major ad-
vance.4,5 In recent years, sentinel lymph node biopsy (SLNB)
has become an important adjunct to full dissection of the
axilla. With the addition of thorough examination by step
sectioning and immunohistochemistry, the staging of women
with invasive breast cancer has potentially achieved greater
accuracy. In addition, the SLNB technique allows identifica-
tion of additional drainage pathways in individual patients.6
The implication of this is yet to be determined but, increasing-
ly, evidence mounts for its importance.7 SLNB may therefore
provide additional information regarding axillary lymph node
involvement either alone or in combination with AC, and may
limit the morbidity associated with axillary surgery.
At the time of designing the Sentinel Node versus Axillary
Clearance (SNAC) trial, various validation studies indicated
that, with optimal techniques, SLNB would be able to predict
the status of the remaining axillary lymph nodes in 95–100%
of cases.8–11 It was determined by the Breast Section of the
Royal Australasian College of Surgeons (RACS), after broad
consultation with its members, that an Australasian trial was
required. By introducing SLNB in this way, the highest princi-
ples of evidenced-based management would be maintained.
Full members of the Breast Section of the RACS already par-
ticipate in a national audit of all breast cancer cases. By par-
ticipating in the SNAC trial, our members complete a vali-
dation set of cases of SLNB, whereby their individual accu-
racy is evaluated and peer-reviewed. Following submission
of a validation set of 20 consecutive cases, each surgeon is
observed performing SLNB by a surgeon who is experienced
with the technique. In the validation set, SLNB is followed
by AC, and correct identification of the sentinel node is re-
quired in more than 90% of cases.
An Australian and New Zealand trial
Why conduct a randomized controlled trial when SLNB-based
management alone has already been adopted as the standard
of care in many parts of the world? Other trials had been
established and were accruing at various rates, some very
slowly. Breast surgeons in Australia have demonstrated com-
mitment to evidence-based medicine and scientific rigour
through the rapid adoption of clinical practice guidelines.12
There was also a level of enthusiasm for clinical trials and a
great deal of support from government and consumer orga-
nizations for the approach adopted. The SNAC trial is compa-
rable to and complements US, UK and European studies. It
focuses on patient ratings of arm swelling, symptoms and
function, body image and quality of life. The radiocolloid
antimony sulfur colloid is ideally suited for lymphatic map-
ping and is arguably superior to radiopharmaceuticals avail-
able elsewhere. The SNAC trial specifies peritumoural injec-
tion, which is suggested will detect extra-axillary sentinel nodes
more efficiently.6 While it is expected to be possible to answer
the question of accuracy and procedure-related morbidity
relatively quickly, it will be some time before confident conclu-
sions can be reached about local recurrence and disease-free
survival. The study was designed to facilitate a prospective
meta-analysis of disease-free and overall survival. The com-
bined analysis of existing studies will more rapidly enable us to
answer these important questions with confidence.
Methods
Eligibility and study design
The SNAC trial is a multicentre, centrally randomized, phase
III clinical trial. Some results from the first planned interim
analysis (of 150 subjects) are reported in this paper. Total
accrual to this study will be 1,100 subjects. The National
Health & Medical Research Council (NHMRC) Clinical Trials
Centre, following confirmation of eligibility, randomizes
women to SLNB plus immediate AC (control arm) or SLNB
alone (experimental arm). Randomization is stratified to en-
sure balance for the following factors: age (< 50 vs * 50 years),
primary tumour (palpable vs impalpable), lymphatic map-
ping technique (blue dye plus lymphoscintigraphy vs blue
dye alone), and institution.
Patients in the experimental arm undergo SLNB alone if
the sentinel node is free of tumour (negative), but completion
AC if the sentinel node contains metastatic tumour (positive)
either on standard examination or following immunohisto-
chemistry.
All women with histologically or cytologically confirmed
operable invasive breast cancer less than 3.0 cm in diameter,
in whom axillary staging is required as part of their treatment,
are eligible. Major exclusion criteria include tumours more
than 3.0 cm in diameter, clinically involved axillary nodes,
multicentric cancer, previously treated breast cancer, pre-
vious axillary surgery, failure to give informed consent, and
ductal carcinoma in situ only.
Surgery and patient management
All surgeons who wish to participate must submit a log of 20
consecutive operations for breast cancer where SLNB was per-
formed, which is reviewed by the Management Committee.
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Following approval of the log, a site visit to assess surgical
technique and nuclear medicine facilities is conducted.
Eligible women undergo the normal preoperative assess-
ment and, in addition, undergo measurement of their arm
volumes12 and detailed evaluation of sensation in the arms. All
women complete a quality-of-life questionnaire (patient self-
rating of arm symptoms, EORTC-QLQ–C30,13 QLM–B2314
and Body Image After Breast Cancer15).
Subjects undergo initial SLNB using the combined blue
dye and lymphoscintigraphic techniques. Where nuclear medi-
cine facilities are not available, localization of the sentinel
node is performed using blue dye alone. These cases will be
stratified separately.
Preoperatively, 20–40 MBq of technetium 99m-labelled
antimony colloid in 2–4 mL of solution is injected around the
tumour at four sites on the day of, or day preceding, surgery.
Nuclear medicine staff identify the sentinel node on lympho-
scintiscan and mark its location on the skin. Intraoperative-
ly, patent blue V is injected in a volume of 2–4 mL in four sites
in peritumoural locations immediately after induction of
anaesthesia.
All sentinel nodes identified in the axilla, including those
in extra-axillary sites where possible, are removed. Wide local
excision or mastectomy is performed in the usual manner.
The surgeon defaults to an axillary dissection if the patient
has been randomized to SLNB only and no sentinel nodes are
identified. Sentinel nodes are defined and deemed to be true
sentinel nodes if they are: “hot” (radioactivity > 10= back-
ground); significantly “blue” in isolation and in relation to
surrounding tissue; or if efferent blue lymphatic channels
converge upon and end at a given node whether or not it is
“hot” or “blue”. Excised sentinel nodes are identified sepa-
rately as SN 1, 2, 3, etc, according to the radioactivity detected
at the time of surgery. They are also designated as “hot and
blue”, “blue not hot” or “hot not blue”.
Pathology
Each entire node is grossly sliced into 2 mm slices and four step
sections prepared at 200 +m intervals. If the node contains
grossly visible metastatic disease, only one section is required.
Sections will also be prepared on coated slides and stained
with the anti-keratin antibody CAM 5.2 to detect smaller
metastases. Non-sentinel nodes will be examined in the
normal way, each node being examined with one haematoxy-
lin and eosin (H & E) section. Intraoperative identification
of possible lymph node metastasis is permitted with either
frozen section or imprint/touch preparation cytology.
Study outcomes
The principal objective of this study is to determine whether
SLNB (with AC only if SLNB is positive) results in less mor-
bidity than immediate AC, with equivalent cancer-related
outcomes, in women with early breast cancer. The detailed
objectives of the study are to compare the effects of SLNB
versus AC in women with early breast cancer on: axillary
morbidity; observer- and self-rating of arm swelling, symp-
toms and function; number of surgical episodes and total
number of days in hospital; use of adjuvant therapies; other
aspects of quality of life; axillary recurrence rates; and, in
time and by meta-analysis, overall survival and disease-free
survival (local, distant and both).
The numbers of axillary recurrences, relapses and deaths
will be small and, thus, a more realistic outcome will be a re-
duction in arm swelling. In addition, a comparison of SLNB
with immediate AC will be made in terms of optimal mea-
sures of arm swelling, symptoms and function, and to deter-
mine what constitutes clinically important differences in
these measures.
The sample size has been calculated to detect differences
in arm swelling and self-ratings of arm symptoms and func-
tions. A sample size of 1,000 patients will have the power to
detect a difference of 6% in arm swelling from 15% in the AC
arm to 9% for those patients allocated to SLNB using a two-
sided test, 80% power and 95% confidence. This sample size
will also provide adequate power to detect a 10-point differ-
ence in the 100-point quality-of-life scales used in the study
for patient-rated arm symptoms and functions. The primary
analyses for the study will be in an intention-to-treat popu-
lation, while secondary analyses will include only patients
found to have negative sentinel nodes (in both arms). Time-
to-event analyses (e.g. time to recurrence, overall survival)
will be summarized with Kaplan-Meier curves and compared
using log-rank tests. Adjustments for prognostic factors will
be made using Cox’s proportional hazards model or other
suitable regression models.
Definitive evidence to draw conclusions about axillary
recurrences and breast cancer deaths will eventually require a
meta-analysis of currently open randomized trials. Therefore,
the effects of SLNB on these outcomes will not be known at
the immediate conclusion of this trial.
All participating hospitals are required to obtain ethics
committee approval. The approved patient information and
consent sheets must first be lodged with the NHMRC Clinical
Trials Centre, and written informed consent is obtained from
all patients prior to randomization.
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Follow-up and assessments
Women are assessed at 1, 6 and 12 months, and then yearly for
5 years. Measurements of arm volume,12 sensation and shoul-
der movement are recorded, and quality-of-life questionnaires
completed at each assessment.14,16 Survival and disease status
will be collected indefinitely. Standard adjuvant treatments
will be prescribed according to local institutional protocols.
Interim analyses
A second interim analysis occurs 3 months after randomiza-
tion of the first 500 women in addition to the stage 1 analysis
of the first 150 women. The purpose of this analysis is to verify
the safety and feasibility of the study procedures and treat-
ments. The key outcome measures for the interim analyses
will include: the proportions of patients in whom sentinel
nodes are successfully identified and biopsied; the numbers of
haematomas, aspirations for seromas and grade 3 or greater
infections; locoregional recurrence rates; and the proportion
of women with significant arm swelling.
Such reviews will be undertaken blinded to any outcome
results by treatment. Interim analyses will be performed by the
study statistician and reviewed by the independent Safety
and Data Monitoring Committee (SDMC) and Management
Committee. The SDMC consists of four people independent
of the trial. The function of the SDMC is to make recom-
mendations to the trial management committee regarding
continuation, cessation or modification of the trial based on
clear evidence from the interim analyses that sentinel nodes
are not successfully identified and biopsied in more than 90%
of subjects, or that morbidity is significantly different between
the treatments.
Results of stage 1 analysis
The trial commenced in May 2001. Randomization continues
at the rate of about 30 subjects per month (total, 1,012 at the
time of writing) from 32 participating centres in Australia and
New Zealand (Table 1). In order to ensure that there is ade-
quate statistical power to answer the study question, recruit-
ment was extended to 1,100 patients (to account for patients
crossing over, and so on). Recruitment to the SNAC trial has
exceeded expectations, and it is anticipated that target accrual
(1,100 patients) will be reached in late 2004. A log of all cases
of breast cancer is kept in 10 of the centres to determine the
rate of eligibility and of recruitment of eligible women. Data
on 622 women assessed between November 2001 and Septem-
ber 2002 revealed that 54% (335) were ineligible due to tumour
size or axillary involvement. Of the 287 (46%) eligible wom-
en, 166 (58%) were randomized to the trial, 23 (8%) were not
offered participation, and 98 (34%) declined to participate.
Baseline characteristics of the first 150 women recruited
are summarized in Table 2. Surgical technique involved pre-
operative lymphoscintigraphy and intraoperative gamma
probe with patent blue dye in 142 cases. In six cases, blue dye
alone was used. In one case, blue dye and a gamma probe were
used in combination. In the last case, lymphoscintigraphy
was performed and the sentinel node was identified with the
assistance of blue dye alone.
Of the 239 sentinel nodes identified and removed, 220
were located in the axilla, five in the internal mammary chain
and nine at other sites (intramammary, 4; supraclavicular, 1;
not stated, 4); records were incomplete for five. Compliance
with randomized treatment is summarized in Table 3. All
treatment was completed as defined by the protocol except
for one case where AC was not done as allocated. The test per-
formance measures for SLNB are available for the control
arm and are summarized in Table 4. This indicates a sensitiv-
ity of 95% (20/21), a false-negative rate of 5% (1/21), and a
negative predictive value of 98% (52/53).
Discussion
Other multi-institution trials
The first two studies described below have similar eligibility
criteria. The target populations are women with operable
invasive primary breast cancer and clinically node-negative
axillae. Overall, the aims are to determine whether SLNB alone
will result in less treatment-related morbidity and, at the same
time, provide equivalent or improved treatment outcomes.
The third study described below tests the hypothesis that
axillary clearance is not required for minimal node-positive
disease and is not really comparable to the SNAC study except
for some aspects of arm-related morbidity.
The National Surgical Adjuvant Breast and Bowel Project
(NSABP) protocol B-32 is a randomized phase III clinical trial
with stratification by age () 49, * 50 years), clinical tumour
size () 2.0, 2.1–4.0, * 4.1 cm) and surgical treatment plan
(lumpectomy, mastectomy). Patients older than 17 years with
a life expectancy of greater than 10 years are eligible. Provided
patients have been disease-free for more than 5 years, a previ-
ous malignancy is not an exclusion. Patients are randomized
to SLNB followed by immediate AC or SLNB and intraoperative
evaluation. Frozen section is not allowed and intraoperative
evaluation is by touch preparation cytology. Patients with a
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negative sentinel node have no further treatment, but the
finding of a positive sentinel node is followed by immediate
AC or delayed AC if sentinel node positivity is confirmed
postoperatively. Primary outcomes focus on locoregional
control and survival. There is a less-detailed assessment of
arm and shoulder morbidity, and additional primary out-
come measures. The study aims to accrue 4,000 patients with
follow-up over 8 years. This is the largest multi-institutional
study with the best chance of answering the primary questions
about recurrence if it accrues satisfactorily.
Axillary Lymphatic Mapping Against Nodal Axillary Clear-
ance (ALMANAC) is a two-stage, multicentre trial in which
stage 1 involves an audit of the technique performed by par-
ticipating surgeons. When this has been successfully completed,
surgeons enter stage 2, the randomized controlled trial. Strati-
fication is by age and screen-detected and symptomatic tumour.
Males are eligible and the age criteria are 18–85 years. Patients
are randomized to axillary lymph node dissection (ALND)
without SLNB, or SLNB alone-based management. The pri-
mary outcomes are axillary morbidity, quality of life and re-
source costs. In the UK, funding does not exist for SLNB per-
formed off trial, so this study should therefore accrue well.
Table 1. Active hospital list and accrual
Number of patients Date activated
Royal Adelaide Hospital, South Australia 141 27/04/01
Westmead Hospital, New South Wales 105 08/10/01
Royal Melbourne Hospital, Victoria 65 15/08/01
North Shore Hospital, New Zealand 61 18/01/02
Waikato Hospital, New Zealand 67 25/03/02
Nambour Hospital, Queensland 80 31/10/01
Princess Alexandra Hospital, Queensland 49 02/05/01
Mater Medical Centre, Queensland 40 27/04/01
St Andrew’s Hospital, South Australia 37 17/10/01
Wesley Medical Centre, Queensland 32 27/04/01
Sir Charles Gairdner Hospital, Western Australia 53 11/12/01
Coff’s Harbour Base Hospital, New South Wales 37 22/04/02
Baringa Private Hospital, New South Wales 30 22/04/02
Mater Adult Hospital, Queensland 35 29/04/02
Concord Hospital, New South Wales 17 09/10/01
Palmerston North Hospital, New Zealand 49 16/12/02
Strathfield Private Hospital, New South Wales 10 04/12/01
Royal Women’s Hospital, Victoria 14 22/10/02
Queen Elizabeth Hospital, South Australia 7 10/05/02
St Vincent’s Hospital, Victoria 11 07/06/02
Western Breast Clinic, South Australia 4 22/02/02
St Vincent’s & Mater Health Sydney, New South Wales 2 31/05/02
Middlemore Hospital, New Zealand 7 12/12/02
Nepean Hospital, New South Wales 12 16/09/02
Royal Prince Alfred Hospital, New South Wales 3 11/12/01
Bankstown-Lidcombe Hospital, New South Wales 0 16/04/02
Lismore Base Hospital, New South Wales 11 04/07/03
St Vincent’s Hospital Lismore, New South Wales 3 25/06/03
Geelong Hospital, Victoria 4 29/08/03
St John of God Health Care Murdoch, Western Australia 17 30/05/03
Auckland Hospital, New Zealand 4 25/09/03
Gold Coast Hospital, Queensland 5 08/10/03
Total recruitment 1,012
Active sites 32
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Locoregional recurrence is a secondary outcome measure.
The sample size is 1,260 patients followed up over a period
of 18 months.
The Axillary Node Dissection in Women with Clinical T1
or T2 N0 M0 Breast Cancer who Have a Positive Sentinel Node
(ACOSOG-Z0011) study assumes SLNB as the standard of
care as distinct from ALND. It is comparing completion ALND
with no immediate additional axillary surgery or axillary-
specific radiation in women with clinical T1 or T2 N0 M0
breast cancer who have a positive sentinel node. Women in
Table 3. Compliance with randomized treatment allocation
(N = 150)
SLNB+AC SLNB
n (%) n (%)
Randomized 75 75
SLNB summary
   SLNB attempted 75 (100) 75 (100)
      Identified and removed 74 (99) 72 (96)
      Identified not removed 1 (1) 0
      Not identified 0 3 (4)
   SLNB+ (cancer detected) 20 (27) 20 (27)
AC summary
   AC performed 74 (99) 23 (31)
      SN identified and removed: SLNB+ 20 (27) 19 (83)
      SN identified and removed: SLNB– 53 (72) 0
      SN identified and not removed 1 (1) 0
      SN not identified 0 3 (13)
      SN outside axilla 0 1 (4)
   AC not performed 1 (1) 52 (69)
      SN identified outside axilla: SLNB– 0 2 (4)
SLNB = sentinel lymph node biopsy; AC = axillary clearance; SN =
sentinel node.
Table 2. Baseline clinical data for the first 150 patients
n (%)
Age (yr)
   < 40 4 (3)
   40–49 19 (13)
   50–59 44 (29)
   60–69 59 (39)
   70–79 23 (15)
   > 79 1 (1)
Method of definitive diagnosis
   Cytological 79 (53)
   Core biopsy 56 (37)
   Open biopsy 15 (10)
Tumour presentation
   Symptomatic 61 (41)
   Asymptomatic and screen-detected 89 (59)
Side of tumour
   Left 79 (53)
   Right 71 (47)
Position of tumour
   Upper outer 76 (51)
   Upper inner 19 (13)
   Central 19 (13)
   Lower inner 14 (9)
   Lower outer 22 (15)
Clinically palpable
   Not palpable 71 (47)
   Palpable 79 (53)
Method of sentinel node localization
   Lymph + Gamma + Blue 142 (95)
   Lymph + Blue 1 (1)
   Gamma + Blue 1 (1)
   Blue alone 6 (4)
Quality of life questionnaires
   Questions not completed 3 (2)
   Questions completed 147 (98)
Lymph = lymphoscintigraphy; Gamma = gamma probe; Blue = blue
dye.
Table 4. Test performance measures for sentinel lymph node
biopsy (control arm only)
Axillary lymph node status
(including the sentinel node)
Cancer No cancer All
Sentinel node status
   Positive 20 10 20
   Negative 11 52 53
   All 21 52 73
both arms will then have whole-breast radiation therapy and
systematic adjuvant therapy. It aims to assess whether overall
survival among patients randomized to no immediate ALND
is essentially equivalent to (or better than) that among pa-
tients assigned to completion ALND, and to determine whether
there is a 6% reduction in overall survival for no immediate
ALND. Investigators will also quantify and compare the sur-
gical morbidities associated with SLNB plus ALND versus
SLNB alone. The study is powered to determine whether there
is an 8% difference in arm swelling in the two arms.
Single-institution prospective randomized trials
A recently published trial reported the results from 516 pa-
tients with primary invasive breast cancer (< 2 cm and clinically
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node-negative) who were randomized to SLNB and ALND or
SLNB with ALND only if the sentinel node was positive.17 The
overall accuracy of SLNB was 96.9%, the sensitivity was 91.2%
and the specificity was 100%. These were the primary endpoints
of the study. Among the 167 patients who did not undergo
axillary dissection, there have been no cases of axillary recur-
rence with a median follow-up of 46 months. This trial alone
does not have the power to measure small incremental gains or
losses in locoregional control or long-term survival. The trial
is a significant addition to an already large body of valida-
tion studies suggesting that the SLNB technique has very
high accuracy. It will not be possible to include these data in a
prospective meta-analysis, which could be achieved by pooling
the existing currently open multi-institutional studies.
Conclusions
The SNAC trial is the first large multicentre study of surgical
treatment of breast cancer to be conducted in Australia and
New Zealand. The rapid recruitment of women and participat-
ing centres indicates that the target of 1,100 subjects will be
met rapidly, allowing for the analysis of study outcomes to be
conducted in a timely manner. The preliminary analysis has
established the ability of both participating women and sur-
geons to comply with the treatment allocated at randomization
and achieve acceptable standards of surgical technique. This
bodes well for a successful conclusion in terms of analysis of
most of the study outcomes. This trial does not have the power
to detect differences in recurrence and survival, but the simi-
larity of this design to other international studies such as
ALMANAC and NSABP-B32 will allow its inclusion in a future
meta-analysis of SLNB. Discussions are under way to establish
a prospective meta-analysis that could accelerate the process
of accruing sufficient women to draw conclusions about the
effect of SLNB on long-term survival. However, the SNAC trial
will provide important new information about the quality of
life of Australian women after breast cancer surgery, the rela-
tionship between subjective and objective changes in arm
symptoms over time, and lymphoedema. It will contribute
significantly to the collective knowledge of the morbidity of
axillary surgery and its consequences.
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